非药物及非生物制剂治疗中轴型脊柱关节炎的疗效与安全性:为2016年ASAS/EULAR推荐更新提供的系统文献综述
该系统文献综述评估了2009至2016年间非药物、非生物药物及手术治疗中轴型脊柱关节炎的疗效与安全性,共纳入45篇论文和2篇摘要。结果证实规律锻炼可能改善疾病活动度、功能和脊柱活动度,NSAIDs疗效得到确认且未发现新安全信号,糖皮质激素未被证明有效,csDMARDs缺乏新数据。
要点
- 规律锻炼可能改善疾病活动度、功能和脊柱活动度。
- NSAIDs疗效确认且无新安全信号,持续与按需使用对mSASSS变化影响不一致。
- 糖皮质激素未被证明有效,csDMARDs缺乏新试验数据。
核心结论
- 规律锻炼可能改善中轴型脊柱关节炎患者的多个结局。
- NSAIDs在中轴型脊柱关节炎中的疗效和安全性得到确认。
- 糖皮质激素未被证明对中轴型脊柱关节炎有效,且缺乏csDMARDs的新数据。
研究设计与样本
- 系统文献综述,检索2009至2016年非药物、非生物药物(除外靶向合成DMARDs)及手术治疗中轴型脊柱关节炎的研究。
- 纳入随机对照试验和临床对照试验评估疗效与安全性,观察性研究需有对照用于安全性评估。
- 共纳入45篇论文和2篇摘要,研究异质性过大未进行数据合并。
主要发现
- 非药物研究异质性很大,但总体证实规律锻炼有益,在疾病活动度、功能和脊柱活动度方面有小的改善。
- 关于NSAIDs的新研究证实其疗效,未发现新的安全信号。
- 在C反应蛋白正常(≤5 mg/L)的强直性脊柱炎患者中,持续使用NSAIDs相比按需使用未减少2年内mSASSS平均变化(0.9 vs 0.8;p=0.62)。
- 在C反应蛋白高的患者中,持续与按需使用NSAIDs对mSASSS变化结果不一致(阳性RCT:0.2 vs 1.7;p=0.003;阴性RCT:1.68 vs 0.96;p=0.28)。
- 短期高剂量全身糖皮质激素显示有限疗效。
关键数值与推荐
- 在C反应蛋白正常(≤5 mg/L)的强直性脊柱炎患者中,持续与按需使用NSAIDs的mSASSS平均变化为0.9 vs 0.8(p=0.62)。
- 在C反应蛋白高的患者中,一项RCT显示持续与按需使用NSAIDs的mSASSS变化为0.2 vs 1.7(p=0.003),另一项RCT为1.68 vs 0.96(p=0.28)。
临床怎么用
- 对于中轴型脊柱关节炎患者,可推荐规律锻炼以可能改善疾病活动度、功能和脊柱活动度。
- NSAIDs仍为中轴型脊柱关节炎的有效治疗选择,未发现新安全信号。
- 糖皮质激素未被证明有效,不推荐作为中轴型脊柱关节炎的常规治疗。
- csDMARDs缺乏新的疗效与安全性数据,需结合既往推荐使用。
局限性
- 研究异质性过大,未能进行数据合并。
- 非药物研究异质性很大,仅能总体描述获益。
- 未检索到csDMARDs的新试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthritis (axSpA) to inform the update of the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of axSpA. A systematic literature review (2009-2016) of all non-pharmacological treatments, non-biological drugs (except targeted synthetic disease-modifying antirheumatic drugs (DMARDs)) and surgical therapies was performed. Randomised controlled trials (RCTs) and clinical controlled trials were assessed for efficacy and safety, while observational studies with a comparator were assessed for safety. All relevant efficacy and safety outcomes were included. Study heterogeneity precluded data pooling. If possible, Cohen's effect size was calculated for non-pharmacological treatments. In total, 45 papers and 2 abstracts were included. Studies on non-pharmacological treatments were very heterogeneous but overall confirmed a benefit for regular exercises, with small improvements in disease activity, function and spinal mobility. New studies on non-steroidal anti-inflammatory drugs (NSAIDs) confirmed their efficacy and new safety signals were not found. NSAIDs used continuously compared with on-demand did not reduce the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) mean change over 2 years in patients with ankylosing spondylitis with normal C reactive protein (CRP; ≤5 mg/L) (1 'negative' RCT (0.9 vs 0.8; p=0.62)), while for patients with high CRP, conflicting results were found (1 'positive' RCT (0.2 vs 1.7; p=0.003), 1 'negative' RCT (1.68 vs 0.96; p=0.28)). No new trials were found for conventional synthetic DMARDs (csDMARDs). Short-term high-dose systemic glucocorticoids showed limited efficacy. Regular exercises may improve several outcomes. Efficacy and safety of NSAIDs in axSpA are confirmed. Glucocorticoids are not proven to be effective in axSpA and new data on csDMARDs are lacking.
引用
- Regel A, Sepriano A, Baraliakos X, et al. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017. PMID: 28176966. doi:10.1136/rmdopen-2016-000397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。